Статья
Миокардиты у взрослых. Клинические рекомендации 2020
Российское кардиологическое общество (РКО)При участии: Евразийской ассоциации терапевтов (ЕАТ), Общества специалистов по сердечной недостаточности (ОССН), Российского научного медицинского общества терапевтов (РНМОТ), Российского общества патологоанатомов, Российского Общества Рентгенологов и Радиологов (РОРР)Одобрено Научно-практическим Советом Минздрава Российской Федерации
1. Maisch B, Pankuweit S. Current treatment options in (peri)myocarditis and inflammatory cardiomyopathy. Herz. 2012;37(6):644-56. doi:10.1007/s00059-012-3679-9.
2. Caforio AL, Calabrese F, Angelini A, et al. A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J. 2007;28(11):1326-33. doi:10.1093/eurheartj/ehm076.
3. Kindermann I, Kindermann M, Kandolf R, et al. Predictors of outcome in patients with suspected myocarditis. Circulation. 2008;118(6):639-48. doi:10.1161/CIRCULATIONAHA.108.769489. Erratum in: Circulation.2008;118(12): e493.
4. Mahrholdt H, Goedecke C, Wagner A, et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation. 2004;109(10):1250-8. doi:10.1161/01.CIR.0000118493.13323.81.
5. Crisan S, Tint D, Petrescu L. Therapeutic Advances in Emergency Cardiology: A Focus on Acute Myocarditis. Am J Ther. 2019;26(2):e294-e300. doi:10.1097/MJT.0000000000000921.
6. Schultheiss HP, Kuhl U, Cooper LT. The management of myocarditis. Eur Heart J. 2011;32(21):2616-25. doi:10.1093/eurheartj/ehr165.
7. Kuhl U, Pauschinger M, Seeberg B, et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation. 2005;112(13):1965-70. doi:10.1161/CIRCULATIONAHA.105.548156.
8. Bowles NE, Ni J, Kearney DL, et al. Detection of viruses in myocardial tissues by polymerase chain reaction. evidence of adenovirus as a common cause of myocarditis in children and adults. J Am Coll Cardiol. 2003;42(3):466-72. doi:10.1016/s0735-1097(03)00648-x.
9. Magnani JW, Danik HJ, Dec GW Jr, DiSalvo TG. Survival in biopsy-proven myocarditis: a long-term retrospective analysis of the histopathologic, clinical, and hemodynamic predictors. Am Heart J. 2006;151(2):463-70. doi:10.1016/j.ahj.2005.03.037.
10. Curigliano G, Cardinale D, Suter T, et al.; ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23 Suppl 7:vii155-66. doi:10.1093/annonc/mds293.
11. Haas SJ, Hill R, Krum H, et al. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 19932003. Drug Saf. 2007;30(1):47-57. doi:10.2165/00002018-200730010-00005.
12. Cook SC, Ferguson BA, Cotes RO, et al. Clozapine-Induced Myocarditis: Prevention and Considerations in Rechallenge. Psychosomatics. 2015;56(6):685-90. doi:10.1016/j.psym.2015.07.002.
13. Арутюнов Г. П., Колесникова Е. А., Беграмбекова Ю.Л. и др. Рекомендации по назначению физических тренировок пациентам с хронической сердечной недостаточностью. Журнал сердечная недостаточность. 2017;18(1):41-66. doi:10.18087/rhfj.2017.1.2339.
14. Curigliano G, Lenihan D, Fradley M, et al. Cardiovascular Toxicity Induced by Chemotherapy, Targeted Agents and Radiotherapy: ESMO Clinical Practice Guidelines | ESMO. Ann Oncol (2020); 31(2): 171-190. doi:10.1016/j.annonc.2019.10.023. URL: https://www.esmo.org/Guidelines/Supportive-and-Palliative-Care/Cardiovascular-Toxicity-Induced-Chemotherapy-Targeted-Agents-and-Radiotherapy (accessed: 17.11.2019).
15. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869-79. doi:10.1002/cncr.11407.
16. Zawadowski GM, Klarich KW, Moder KG, et al. A contemporary case series of lupus myocarditis. Lupus. 2012;21(13):1378-84. doi:10.1177/0961203312456752.
17. Mason JW. Myocarditis and dilated cardiomyopathy: an inflammatory link. Cardiovasc Res. 2003;60(1):5-10. doi:10.1016/s0008-6363(03)00437-1.
18. Gauntt C, Huber S. Coxsackievirus experimental heart diseases. Front Biosci. 2003;8:e23-35. doi:10.2741/928.
19. Engler RJ, Nelson MR, Collins LC Jr, et al. A prospective study of the incidence of myocarditis/pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination. PLoS One. 2015;10(3):e0118283. doi:10.1371/journal.pone.0118283.
20. Pankuweit S, Ruppert V, Maisch B. Inflammation in dilated cardiomyopathy. Herz. 2004;29(8):788-93. doi:10.1007/s00059-004-2626-9.
21. Pankuweit S, Portig I, Maisch B. Pathophysiology of cardiac inflammation: molecular mechanisms. Herz. 2002;27(7):669-76. doi:10.1007/s00059-002-2421-4.
22. Maisch B, Ristic AD, Hufnagel G, Pankuweit S. Pathophysiology of viral myocarditis: the role of humoral immune response. Cardiovasc Pathol. 2002;11(2):112-22. doi:10.1016/s1054-8807(01)00113-2.
23. D'Ambrosio A, Patti G, Manzoli A, et al. The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review. Heart. 2001;85(5):499-504. doi:10.1136/heart.85.5.499.
24. Leone O, Veinot JP, Angelini A, et al. 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol. 2012;21(4):245-74. doi:10.1016/j.carpath.2011.10.001.
25. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organi-zation/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation. 1996;93(5):841-2. doi:10.1161/01.cir.93.5.841.
26. Mason JW, O'Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med. 1995;333(5):269-75. doi:10.1056/NEJM199508033330501.
27. Felker GM, Hu W, Hare JM, et al. The spectrum of dilated cardiomyopathy. The Johns Hopkins experience with 1,278 patients. Medicine (Baltimore). 1999;78(4):270-83. doi:10.1097/00005792-199907000-00005.
28. Towbin JA, Lowe AM, Colan SD, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA. 2006;296(15):1867-76. doi:10.1001/jama.296.15.1867.
29. Cooper LT Jr. Myocarditis. N Engl J Med. 2009;360(15):1526-38. doi:10.1056/NEJMra0800028.
30. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743-800. doi:10.1016/S0140-6736(15)60692-4.
31. Maron BJ, Udelson JE, Bonow RO, et al. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Association and American College of Cardiology. Circulation. 2015;132(22):e273-80. doi:10.1161/CIR.0000000000000239.
32. Karjalainen J, Heikkila J. Incidence of three presentations of acute myocarditis in young men in military service. A 20-year experience. Eur Heart J. 1999;20(15):1120-5. doi:10.1053/euhj.1998.1444.
33. Арутюнов А. Г., Рылова А.К., Арутюнов Г.П. Регистр госпитализированных пациентов с декомпенсацией кровообращения (Павловский регистр). Сообщение 1. Современная клиническая характеристика пациента с декомпенсацией кровообращения. Клинические фенотипы пациентов. Журнал сердечная недостаточность. 2014;15(1):23-32.
34. Wakafuji S, Okada R. Twenty year autopsy statistics of myocarditis incidence in Japan. Jpn Circ J. 1986;50(12):1288-93. doi:10.1253/jcj.50.1288.
35. Gore I, Saphir O. Myocarditis; a classification of 1402 cases. Am Heart J. 1947;34(6):827-30. doi:10.1016/0002-8703(47)90147-6.
36. Basso C, Calabrese F, Corrado D, Thiene G. Postmortem diagnosis in sudden cardiac death victims: macroscopic, microscopic and molecular findings. Cardiovasc Res. 2001;50(2):290-300. doi:10.1016/s0008-6363(01)00261-9.
37. Passarino G, Burlo P, Ciccone G, et al. Prevalence of myocarditis at autopsy in Turin, Italy. Arch Pathol Lab Med. 1997;121(6):619-22.
38. Hufnagel G, Pankuweit S, Richter A, et al. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID). First epidemiological results. Herz. 2000;25(3):279-85. doi:10.1007/s000590050021.
39. Kyto V, Sipila J, Rautava P. Gender differences in myocarditis: a nationwide study in Finland. Eur. Heart J. 2013;34, suppl_1.
40. Kyto V, Sipila J, Rautava P. The effects of gender and age on occurrence of clinically suspected myocarditis in adulthood. Heart. 2013;99(22):1681-4. doi:10.1136/heartjnl-2013-304449.
41. Fairweather D, Cooper LT Jr, Blauwet LA. Sex and gender differences in myocarditis and dilated cardiomyopathy. Curr Probl Cardiol. 2013;38(1):7-46. doi:10.1016/j.cpcardiol.2012.07.003.
42. Saji T, Matsuura H, Hasegawa K, et al. Comparison of the clinical presentation, treatment, and outcome of fulminant and acute myocarditis in children. Circ J. 2012;76(5):1222-8. doi:10.1253/circj.cj-11-1032.
43. Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(33):2636-48, 2648a-2648d. doi:10.1093/eurheartj/eht210.
44. Schultz JC, Hilliard AA, Cooper LT Jr, Rihal CS. Diagnosis and treatment of viral myocarditis. Mayo Clin Proc. 2009;84(11):1001-9. doi:10.1016/S0025-6196(11)60670-8.
45. Klein RM, Jiang H, Niederacher D, et al. Frequency and quantity of the parvovirus B19 genome in endomyocardial biopsies from patients with suspected myocarditis or idiopathic left ventricular dysfunction. Z Kardiol. 2004;93(4):300-9. doi:10.1007/s00392-004-0079-z.
46. Kuhl U, Pauschinger M, Noutsias M, et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction. Circulation. 2005;111(7):887-93. doi:10.1161/01.CIR.0000155616.07901.35.
47. Kuethe F, Lindner J, Matschke K, et al. Prevalence of parvovirus B19 and human bocavirus DNA in the heart of patients with no evidence of dilated cardiomyopathy or myocarditis. Clin Infect Dis. 2009;49(11):1660-6. doi:10.1086/648074.
48. Stewart GC, Lopez-Molina J, Gottumukkala RV, et al. Myocardial parvovirus B19 persistence: lack of association with clinicopathologic phenotype in adults with heart failure. Circ Heart Fail. 2011;4(1):71-8. doi:10.1161/CIRCHEARTFAILURE.110.958249.
49. Lassner D, Rohde M, Siegismund Ch, et al. Myocarditis — Personalized Medicine by Expanded Endomyocardial Biopsy Diagnostics. World J. Cardiovasc. Dis. 2014;4(6):325-40. doi:10.4236/wjcd.2014.46042
50. Pankuweit S, Moll R, Baandrup U, et al. Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens. Hum Pathol. 2003 May;34(5):497-503. doi:10.1016/s0046-8177(03)00078-9.
51. Sabatine MS, Poh KK, Mega JL, et al. Case records of the Massachusetts General Hospital. Case 36-2007. A 31-year-old woman with rash, fever, and hypotension. N Engl J Med. 2007;357(21):2167-78. doi:10.1056/NEJMcpc079030.
52. Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. Eur Heart J. 2007;28(24):3076-93. doi:10.1093/eurheartj/ehm456.
53. Kindermann I, Barth C, Mahfoud F, et al. Update on myocarditis. J Am Coll Cardiol. 2012;59(9):779-92. doi:10.1016/j.jacc.2011.09.074.
54. Sagar S, Liu PP, Cooper LT Jr. Myocarditis. Lancet. 2012;379(9817):738-47. doi:10.1016/S0140-6736(11)60648-X.
55. Dennert R, Crijns HJ, Heymans S. Acute viral myocarditis. Eur Heart J. 2008;29(17): 2073-82. doi:10.1093/eurheartj/ehn296.
56. McCarthy RE 3rd, Boehmer JP, Hruban RH, et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med. 2000;342(10):690-5. doi:10.1056/NEJM200003093421003.
57. Dec GW. Introduction to clinical myocarditis. In: Cooper L. T., ed. Myocarditis: From Bench to Bedside. Totowa, NJ: Humana Press 2003;257-81.
58. Baccouche H, Mahrholdt H, Meinhardt G, et al. Diagnostic synergy of non-invasive cardiovascular magnetic resonance and invasive endomyocardial biopsy in troponinpositive patients without coronary artery disease. Eur Heart J. 2009;30(23):2869-79. doi:10.1093/eurheartj/ehp328.
59. Frustaci A, Verardo R, Caldarulo M, et al. Myocarditis in hypertrophic cardiomyopathy patients presenting acute clinical deterioration. Eur Heart J. 2007;28(6):733-40. doi:10.1093/eurheartj/ehl525.
60. Dec GW Jr, Waldman H, Southern J, et al. Viral myocarditis mimicking acute myocardial infarction. J Am Coll Cardiol. 1992;20(1):85-9. doi:10.1016/0735-1097(92)90141-9.
61. Ferreira VM, Piechnik SK, Dall'Armellina E, et al. T(1) mapping for the diagnosis of acute myocarditis using CMR: comparison to T2-weighted and late gadolinium enhanced imaging. JACC Cardiovasc Imaging. 2013;6(10):1048-58. doi:10.1016/j.jcmg.2013.03.008.
62. Abdel-Aty H, Boye P, Zagrosek A, et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol. 2005;45(11):1815-22. doi:10.1016/j.jacc.2004. 11.069.
63. van Nierop J, Limburg A, van Ofwegen-Hanekamp CEE. Myocarditis mimicking acute myocardial infarction. Neth Heart J. 2015;23(10):502-4. doi:10.1007/s12471-015-0732-3.
64. Basman C, Agrawal PR, McRee C, et al. Diagnostic Approach to Myocarditis Mimicking Myocardial Infarction at Initial Presentation. Cardiol Res. 2016;7(6):209-13. doi:10.14740/cr485w.
65. Kuhl U, Pauschinger M, Bock T, et al. Parvovirus B19 infection mimicking acute myocardial infarction. Circulation. 2003;108(8):945-50. doi:10.1161/01.CIR.0000085168.02782.2C.
66. Basic D, Gupta S, Kwong RY. Parvovirus b19-induced myocarditis mimicking acute myocardial infarction: clarification of diagnosis by cardiac magnetic resonance imaging. Circulation. 2010;121(7):e40-2. doi:10.1161/CIR.0b013e3181d310ea.
67. Collier RJ. Diphtheria toxin: mode of action and structure. Bacteriol Rev. 1975;39(1):54-85. doi:10.1128/br.39.1.54-85.1975.
68. Stockins BA, Lanas FT, Saavedra JG, Opazo JA. Prognosis in patients with diphtheric myocarditis and bradyarrhythmias: assessment of results of ventricular pacing. Br Heart J. 1994;72(2):190-1. doi:10.1136/hrt.72.2.190.
69. Bethell DB, Nguyen Minh Dung, Ha Thi Loan, et al. Prognostic value of electrocardiographic monitoring of patients with severe diphtheria. Clin Infect Dis. 1995;20(5):1259-65. doi:10.1093/clinids/20.5.1259.
70. Mestroni L, Maisch B, McKenna WJ, et al. Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. Eur Heart J. 1999;20(2):93-102. doi:10.1053/euhj.1998.1145.
71. Brady WJ, Ferguson JD, Ullman EA, Perron AD. Myocarditis: emergency department recognition and management. Emerg Med Clin North Am. 2004;22(4):865-85. doi:10.1016/j.emc.2004.05.010.
72. Brown CA, O'Connell JB. Implications of the Myocarditis Treatment Trial for clinical practice. Curr Opin Cardiol. 1996;11(3):332-6. doi:10.1097/00001573-199605000-00014.
73. Deswal A, Petersen NJ, Feldman AM, et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation. 2001;103(16):2055-9. doi:10.1161/01.cir.103.16.2055.
74. Lauer B, Schannwell M, Kuhl U, et al. Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis. J Am Coll Cardiol. 2000;35(1):11-8. doi:10.1016/s0735-1097(99)00485-4.
75. Heymans S. Myocarditis and heart failure: need for better diagnostic, predictive, and therapeutic tools. Eur Heart J. 2007;28(11):1279-80. doi:10.1093/eurheartj/ehm111.
76. deFilippi CR, de Lemos JA, Christenson RH, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA. 2010;304(22):2494-502. doi:10.1001/jama.2010.1708.
77. Deardorff R, Spinale FG. Cytokines and matrix metalloproteinases as potential biomarkers in chronic heart failure. Biomark Med. 2009;3(5):513-23. doi:10.2217/bmm.09.60.
78. Emdin M, Vittorini S, Passino C, Clerico A. Old and new biomarkers of heart failure. Eur J Heart Fail. 2009;11(4):331-5. doi:10.1093/eurjhf/hfp035.
79. Caforio AL, Mahon NG, Baig MK, et al. Prospective familial assessment in dilated cardiomyopathy: cardiac autoantibodies predict disease development in asymptomatic relatives. Circulation. 2007;115(1):76-83. doi:10.1161/CIRCULATIONAHA.106.641472.
80. Zhang L, Hu D, Li J, et al. Autoantibodies against the myocardial beta1-adrenergic and M2-muscarinic receptors in patients with congestive heart failure. Chin Med J (Engl). 2002;115(8):1127-31.
81. Maisch B, Richter A, Sandmoller A, et al.; BMBF-Heart Failure Network. Inflammatory dilated cardiomyopathy (DCMI). Herz. 2005;30(6):535-44. doi:10.1007/s00059-005-2730-5.
82. Frustaci A, Chimenti C, Calabrese F, et al. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation. 2003;107(6):857-63. doi:10.1161/01.cir.0000048147.15962.31.
83. Staudt A, Staudt Y, Dorr M, et al. Potential role of humoral immunity in cardiac dysfunction of patients suffering from dilated cardiomyopathy. J Am Coll Cardiol. 2004;44(4):829-36. doi:10.1016/j.jacc.2004.04.055.
84. Stork S, Boivin V, Horf R, et al. Stimulating autoantibodies directed against the cardiac beta1-adrenergic receptor predict increased mortality in idiopathic cardiomyopathy. Am Heart J. 2006;152(4):697-704. doi:10.1016/j.ahj.2006.05.004.
85. Warraich RS, Noutsias M, Kazak I, et al. Immunoglobulin G3 cardiac myosin autoantibodies correlate with left ventricular dysfunction in patients with dilated cardiomyopathy: immunoglobulin G3 and clinical correlates. Am Heart J. 2002;143(6):1076-84. doi:10.1067/mhj.2002.124406. Erratum in: Am Heart J. 2003;145(2):213. Kasac Ilkay.
86. Deubner N, Berliner D, Schlipp A, et al.; Etiology, Titre-Course, and Survival-Study Group. Cardiac beta1-adrenoceptor autoantibodies in human heart disease: rationale and design of the Etiology, Titre-Course, and Survival (ETiCS) Study. Eur J Heart Fail. 2010;12(7):753-62. doi:10.1093/eurjhf/hfq072.
87. Mahfoud F, Gartner B, Kindermann M, et al. Virus serology in patients with suspected myocarditis: utility or futility? Eur Heart J. 2011;32(7):897-903. doi:10.1093/eurheartj/ehq493.
88. Liu P, Martino T, Opavsky MA, Penninger J. Viral myocarditis: balance between viral infection and immune response. Can J Cardiol. 1996;12(10):935-43.
89. Klingel K, Hohenadl C, Canu A, et al. Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: quantitative analysis of virus replication, tissue damage, and inflammation. Proc Natl Acad Sci U S A. 1992;89(1):314-8. doi:10.1073/pnas.89.1.314.
90. Baboonian C, Treasure T. Meta-analysis of the association of enteroviruses with human heart disease. Heart. 1997;78(6):539-43. doi:10.1136/hrt.78.6.539.
91. Mahrholdt H, Wagner A, Deluigi CC, et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation. 2006;114(15):1581-90. doi:10.1161/CIRCULATIONAHA.105.606509.
92. Grun S, Schumm J, Greulich S, et al. Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. J Am Coll Cardiol. 2012;59(18):1604-15. doi:10.1016/j.jacc.2012.01.007.
93. Ukena C, Mahfoud F, Kindermann I, et al. Prognostic electrocardiographic parameters in patients with suspected myocarditis. Eur J Heart Fail. 2011;13(4):398-405. doi:10.1093/eurjhf/hfq229.
94. JCS Joint Working Group. Guidelines for diagnosis and treatment of myocarditis (JCS 2009): digest version. Circ J. 2011;75(3):734-43. doi:10.1253/circj.cj-88-0008.
95. Yilmaz A, Klingel K, Kandolf R, Sechtem U. Imaging in inflammatory heart disease: from the past to current clinical practice. Hellenic J Cardiol. 2009;50(6):449-60.
96. Felker GM, Boehmer JP, Hruban RH, et al. Echocardiographic findings in fulminant and acute myocarditis. J Am Coll Cardiol. 2000;36(1):227-32. doi:10.1016/s0735-1097(00)00690-2.
97. Fields CL, Ossorio MA, Roy TM, et al. Thallium-201 scintigraphy in the diagnosis and management of myocardial sarcoidosis. South Med J. 1990;83(3):339-42. doi:10.1097/00007611-199003000-00022.
98. Le Guludec D, Menad F, Faraggi M, et al. Myocardial sarcoidosis. Clinical value of technetium-99m sestamibi tomoscintigraphy. Chest. 1994;106(6):1675-82. doi:10.1378/chest.106.6.1675.
99. O'Connell JB, Henkin RE, Robinson JA, et al. Gallium-67 imaging in patients with dilated cardiomyopathy and biopsy-proven myocarditis. Circulation. 1984;70(1):58-62. doi:10.1161/01.cir.70.1.58.
100. Ohira H, Tsujino I, Yoshinaga K. 18F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis. Eur J Nucl Med Mol Imaging. 2011;38(9):1773-83. doi:10.1007/s00259-011-1832-y.
101. Сафиуллина А. А., Шария М. А., Нарусов О. Ю., и др. Диагностические возможности магнитно-резонансной томографии сердца у больных с воспалительной кардиомиопатией: сопоставление результатов с данными эндомиокардиальной биопсии и клинической картиной. Терапевтический Архив. 2013;85(4):22-8.
102. Puntmann VO, Voigt T, Chen Z, et al. Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. JACC Cardiovasc Imaging. 2013;6(4):475-84. doi:10.1016/j.jcmg.2012.08.019.
103. Voigt A, Elgeti T, Durmus T, et al. Cardiac magnetic resonance imaging in dilated cardiomyopathy in adults — towards identification of myocardial inflammation. Eur Radiol. 2011;21(5):925-35. doi:10.1007/s00330-010-1985-2.
104. Friedrich MG, Sechtem U, Schulz-Menger J, et al.; International Consensus Group on Cardiovascular Magnetic Resonance in Myocarditis. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol. 2009;53(17):1475-87. doi:10.1016/j.jacc.2009.02.007.
105. Kellman P, Wilson JR, Xue H, et al. Extracellular volume fraction mapping in the myocardium, part 1: evaluation of an automated method. J Cardiovasc Magn Reson. 2012;14(1):63. doi:10.1186/1532-429X-14-63.
106. Сафиуллина А.А., Нарусов О.Ю., Шария М.А. и др. Роль магнитнорезонансной томографии в диагностике воспалительных заболеваний миокарда. Кардиологический Вестник. 2012;7(1):41-6.
107. Rottgen R, Christiani R, Freyhardt P, et al. Magnetic resonance imaging findings in acute myocarditis and correlation with immunohistological parameters. Eur Radiol. 2011;21(6):1259-66. doi:10.1007/s00330-010-2022-1.
108. Luetkens JA, Homsi R, Dabir D, et al. Comprehensive Cardiac Magnetic Resonance for Short-Term Follow-Up in Acute Myocarditis. J Am Heart Assoc. 2016;5(7):e003603. doi:10.1161/JAHA.116.003603.
109. Gutberlet M, Spors B, Thoma T, et al. Suspected chronic myocarditis at cardiac MR: diagnostic accuracy and association with immunohistologically detected inflammation and viral persistence. Radiology. 2008;246(2):401-9. doi:10.1148/radiol.2461062179.
110. Yilmaz A, Kindermann I, Kindermann M, et al. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation. 2010;122(9):900-9. doi:10.1161/CIRCULATIONAHA.109.924167.
111. Chow LH, Radio SJ, Sears TD, McManus BM. Insensitivity of right ventricular endomyocardial biopsy in the diagnosis of myocarditis. J Am Coll Cardiol. 1989;14(4):915-20. doi:10.1016/0735-1097(89)90465-8.
112. She RC, Hammond EH. Utility of immunofluorescence and electron microscopy in endomyocardial biopsies from patients with unexplained heart failure. Cardiovasc Pathol. 2010;19(4):e99-105. doi:10.1016/j.carpath.2009.04.004.
113. Deckers JW, Hare JM, Baughman KL. Complications of transvenous right ventricular endomyocardial biopsy in adult patients with cardiomyopathy: a seven-year survey of 546 consecutive diagnostic procedures in a tertiary referral center. J Am Coll Cardiol. 1992;19(1):43-7. doi:10.1016/0735-1097(92)90049-s.
114. Shirani J, Freant LJ, Roberts WC. Gross and semiquantitative histologic findings in mononuclear cell myocarditis causing sudden death, and implications for endomyocardial biopsy. Am J Cardiol. 1993;72(12):952-7. doi:10.1016/0002-9149(93)91113-v.
115. Holzmann M, Nicko A, Kuhl U, et al. Complication rate of right ventricular endomyocardial biopsy via the femoral approach: a retrospective and prospective study analyzing 3048 diagnostic procedures over an 11-year period. Circulation. 2008;118(17):1722-8. doi:10.1161/CIRCULATIONAHA.107.743427.
116. Parrillo JE, Aretz HT, Palacios I, et al. The results of transvenous endomyocardial biopsy can frequently be used to diagnose myocardial diseases in patients with idiopathic heart failure. Endomyocardial biopsies in 100 consecutive patients revealed a substantial incidence of myocarditis. Circulation. 1984;69(1):93-101. doi:10.1161/01.cir.69.1.93.
117. Ponikowski P, Voors AA, Anker SD, et al.; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975. doi:10.1002/ejhf.592.
118. Mirabel M, Luyt CE, Leprince P, et al. Outcomes, long-term quality of life, and psychologic assessment of fulminant myocarditis patients rescued by mechanical circulatory support. Crit Care Med. 2011;39(5):1029-35. doi:10.1097/CCM.0b013e31820ead45.
119. Hsu KH, Chi NH, Yu HY, et al. Extracorporeal membranous oxygenation support for acute fulminant myocarditis: analysis of a single center's experience. Eur J Cardiothorac Surg. 2011;40(3):682-8. doi:10.1016/j.ejcts.2010.12.050.
120. Nohria A, Mielniczuk LM, Stevenson LW. Evaluation and monitoring of patients with acute heart failure syndromes. Am J Cardiol. 2005;96(6A):32G-40G. doi:10.1016/j.amjcard.2005.07.019.
121. Forrester JS, Diamond GA, Swan HJ. Correlative classification of clinical and hemodynamic function after acute myocardial infarction. Am J Cardiol. 1977;39(2):137-45. doi:10.1016/s0002-9149(77)80182-3.
122. Park JH, Balmain S, Berry C, et al. Potentially detrimental cardiovascular effects of oxygen in patients with chronic left ventricular systolic dysfunction. Heart. 2010;96(7):533-8. doi:10.1136/hrt.2009.175257.
123. Baronia AK, Azim A, Narula G, et al. Should early venous oximetry be indicated in suspected cases of fulminant myocarditis? Am J Emerg Med. 2007;25(1):122-3. doi:10.1016/j.ajem.2006.05.017.
124. Vital FM, Ladeira MT, Atallah AN. Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary oedema. Cochrane Database Syst Rev. 2013;(5):CD005351. doi:10.1002/14651858.CD005351.pub3.
125. Park M, Sangean MC, Volpe Mde S, et al. Randomized, prospective trial of oxygen, continuous positive airway pressure, and bilevel positive airway pressure by face mask in acute cardiogenic pulmonary edema. Crit Care Med. 2004;32(12):2407-15. doi:10.1097/01.ccm.0000147770.20400.10.
126. Felker GM, Lee KL, Bull DA, et al.; NHLBI Heart Failure Clinical Research Network. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797-805. doi:10.1056/NEJMoa1005419.
127. Ahmad T, Jackson K, Rao VS, et al. Worsening Renal Function in Patients With Acute Heart Failure Undergoing Aggressive Diuresis Is Not Associated With Tubular Injury. Circulation. 2018;137(19):2016-2028. doi:10.1161/CIRCULATIONAHA.117.030112. Erratum in: Circulation. 2018;137(25):e853.
128. Мареев В. Ю., Выгодин В. А., Беленков Ю. Н. ДиУруетическая терапия Эффективными дозами перораЛЬных диуретиков торасемида (Диувер®) и фуросемида в лечении больных с обострением Хронической Сердечной Недостаточности (ДУЭЛЬ-ХСН). Журнал Сердечная Недостаточность. 2011;12(1):3-10.
129. DiNicolantonio JJ. Should torsemide be the loop diuretic of choice in systolic heart failure? Future Cardiol. 2012;8(5):707-28. doi:10.2217/fca.12.54.
130. Murray MD, Deer MM, Ferguson JA, et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med. 2001;111(7):513-20. doi:10.1016/s0002-9343(01)00903-2.
131. Мареев Ю. В., Мареев В. Ю. Характеристика и лечение пациентов с ХСН, госпитализированных в стационар. Кардиология. 2017;57(4S):19-30. doi:10.18087/cardio.2433.
132. Eapen ZJ, Reed SD, Li Y, et al. Do countries or hospitals with longer hospital stays for acute heart failure have lower readmission rates? Findings from ASCEND-HF. Circ Heart Fail. 2013;6(4):727-32. doi:10.1161/CIRCHEARTFAILURE.112.000265.
133. Hernandez AF, Greiner MA, Fonarow GC, et al. Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA. 2010;303(17):1716-22. doi:10.1001/jama.2010.533.
134. Knauf H, Mutschler E. Sequential nephron blockade breaks resistance to diuretics in edematous states. J Cardiovasc Pharmacol. 1997;29(3):367-72. doi:10.1097/00005344-199703000-00010.
135. Martens P, Nijst P, Mullens W. Current Approach to Decongestive Therapy in Acute Heart Failure. Curr Heart Fail Rep. 2015;12(6):367-78. doi:10.1007/s11897-015-0273-5.
136. van Vliet AA, Donker AJ, Nauta JJ, Verheugt FW. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol. 1993;71(3):21A-28A. doi:10.1016/0002-9149(93)90241-4.
137. Butler J, Hernandez AF, Anstrom KJ, et al. Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure. JACC Heart Fail. 2016;4(9):726-35. doi:10.1016/j.jchf.2016.06.003.
138. Bart BA, Goldsmith SR, Lee KL, et al.; Heart Failure Clinical Research Network. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012;367(24):2296-304. doi:10.1056/NEJMoa1210357.
139. Wakai A, McCabe A, Kidney R, et al. Nitrates for acute heart failure syndromes. Cochrane Database Syst Rev. 2013;2013(8):CD005151. doi:10.1002/14651858.CD005151.pub2.
140. Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet. 1998;351(9100):389-93. doi:10.1016/S0140-6736(97)08417-1.
141. Belletti A, Castro ML, Silvetti S, et al. The Effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trials. Br J Anaesth. 2015;115(5):656-75. doi:10.1093/bja/aev284.
142. Mebazaa A, Parissis J, Porcher R, et al. Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods. Intensive Care Med. 2011;37(2):290-301. doi:10.1007/s00134-010-2073-4.
143. Elkayam U, Tasissa G, Binanay C, et al. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart J. 2007;153(1):98-104. doi:10.1016/j.ahj.2006.09.005.
144. Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med. 1998;339(25):1810-6. doi:10.1056/NEJM199812173392503.
145. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991;325(21):1468-75. doi:10.1056/NEJM199111213252103.
146. De Backer D, Biston P, Devriendt J, et al.; SOAP II Investigators. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779-89. doi:10.1056/NEJMoa0907118.
147. Giamouzis G, Butler J, Starling RC, et al. Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. J Card Fail. 2010;16(12):922-30. doi:10.1016/j.cardfail.2010.07.246.
148. Triposkiadis FK, Butler J, Karayannis G, et al. Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial. Int J Cardiol. 2014;172(1):115-21. doi:10.1016/j.ijcard.2013.12.276.
149. Chen HH, Anstrom KJ, Givertz MM, et al.; NHLBI Heart Failure Clinical Research Network. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA. 2013;310(23):2533-43. doi:10.1001/jama.2013.282190.
150. Matsumori A, Igata H, Ono K, et al. High doses of digitalis increase the myocardial production of proinflammatory cytokines and worsen myocardial injury in viral myocarditis: a possible mechanism of digitalis toxicity. Jpn Circ J. 1999;63(12):934-40. doi:10.1253/jcj.63.934.
151. Kivikko M, Pollesello P, Tarvasmaki T, et al. Effect of baseline characteristics on mortality in the SURVIVE trial on the effect of levosimendan vs dobutamine in acute heart failure: Sub-analysis of the Finnish patients. Int J Cardiol. 2016;215:26-31. doi:10.1016/j.ijcard.2016.04.064.
152. Packer M, Colucci W, Fisher L, et al.; REVIVE Heart Failure Study Group. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 2013;1(2):103-11. doi:10.1016/j.jchf.2012.12.004.
153. Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J. 2009;30(16):1995-2002. doi:10.1093/eurheartj/ehp249.
154. Chen HS, Wang W, Wu SN, Liu JP. Corticosteroids for viral myocarditis. Cochrane Database Syst Rev. 2013;2013(10):CD004471. doi:10.1002/14651858.CD004471.pub3.
155. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al.; ESC Scientific Document Group. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793-867. doi:10.1093/eurheartj/ehv316.
156. Pavlicek V, Kindermann I, Wintrich J, et al. Ventricular arrhythmias and myocardial inflammation: Long-term follow-up of patients with suspected myocarditis. Int J Cardiol. 2019;274:132-7. doi:10.1016/j.ijcard.2018.07.142.
157. Chiale PA, Halpern MS, Nau GJ, et al. Efficacy of amiodarone during long-term treatment of malignant ventricular arrhythmias in patients with chronic chagasic myocarditis. Am Heart J. 1984;107(4):656-65. doi:10.1016/0002-8703(84)90311-9.
158. Heart Failure Society Of America. Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2006;12(1):10-38. doi:10.1016/j.cardfail.2005.12.001.
159. Packer M. What causes sudden death in patients with chronic heart failure and a reduced ejection fraction? Eur Heart J. 2020;41(18):1757-63. doi:10.1093/eurheartj/ehz553.
160. Rezkalla S, Kloner RA, Khatib G, et al. Effect of metoprolol in acute coxsackievirus B3 murine myocarditis. J Am Coll Cardiol. 1988;12(2):412-4. doi:10.1016/0735-1097(88)90414-7.
161. Yuan Z, Shioji K, Kihara Y, et al. Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property. Am J Physiol Heart Circ Physiol. 2004;286(1):H83-90. doi:10.1152/ajpheart.00536.2003.
162. Steinbeck G, Bach P, Haberl R. Electrophysiologic and antiarrhythmic efficacy of oral sotalol for sustained ventricular tachyarrhythmias: evaluation by programmed stimulation and ambulatory electrocardiogram. J Am Coll Cardiol. 1986;8(4):949-58. doi:10.1016/s0735-1097(86)80440-5.
163. Boutitie F, Boissel JP, Connolly SJ, et al. Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. Circulation. 1999;99(17):2268-75. doi:10.1161/01.cir.99.17.2268.
164. Kovoor P, Eipper V, Byth K, et al. Comparison of sotalol with amiodarone for long-term treatment of spontaneous sustained ventricular tachyarrhythmia based on coronary artery disease. Eur Heart J. 1999;20(5):364-74. doi:10.1053/euhj.1998.1279.
165. MacNeil DJ, Davies RO, Deitchman D. Clinical safety profile of sotalol in the treatment of arrhythmias. Am J Cardiol. 1993;72(4):44A-50A. doi:10.1016/0002-9149(93)90024-7.
166. Kandolin R, Lehtonen J, Salmenkivi K, et al. Diagnosis, treatment, and outcome of giantcell myocarditis in the era of combined immunosuppression. Circ Heart Fail. 2013;6(1):15-22. doi:10.1161/CIRCHEARTFAILURE.112.969261.
167. Schumm J, Greulich S, Wagner A, et al. Cardiovascular magnetic resonance risk stratification in patients with clinically suspected myocarditis. J Cardiovasc Magn Reson. 2014;16(1):14. doi:10.1186/1532-429X-16-14.
168. Мареев В.Ю., Фомин И. В., Агеев Ф. Т. и др. Клинические рекомендации ОССН — РКО — РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018;58(6S):8-158. doi:10.18087/cardio.2475.
169. Guglin M, Nallamshetty L. Myocarditis: diagnosis and treatment. Curr Treat Options Cardiovasc Med. 2012;14(6):637-51. doi:10.1007/s11936-012-0204-7.
170. Katz SD. Left ventricular thrombus and the incidence of thromboembolism in patients with congestive heart failure: can clinical factors identify patients at increased risk? J Cardiovasc Risk. 1995;2(2):97-102.
171. Cioffi G, Pozzoli M, Forni G, et al. Systemic thromboembolism in chronic heart failure. A prospective study in 406 patients. Eur Heart J. 1996;17(9):1381-9. doi:10.1093/oxfordjournals.eurheartj.a015073.
172. Fuster V, Gersh BJ, Giuliani ER, et al. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol. 1981;47(3):525-31. doi:10.1016/0002-9149(81)90534-8.
173. Stratton JR, Nemanich JW, Johannessen KA, Resnick AD. Fate of left ventricular thrombi in patients with remote myocardial infarction or idiopathic cardiomyopathy. Circulation. 1988;78(6):1388-93. doi:10.1161/01.cir.78.6.1388.
174. Howell MD, Geraci JM, Knowlton AA. Congestive heart failure and outpatient risk of venous thromboembolism: a retrospective, case-control study. J Clin Epidemiol. 2001;54(8):810-6. doi:10.1016/s0895-4356(00)00373-5.
175. Carson PE, Johnson GR, Dunkman WB, et al. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87(6 Suppl):VI102-10.
176. Lip GY, Piotrponikowski P, Andreotti F, et al.; Heart Failure Association (EHFA) of the European Society of Cardiology (ESC) and the ESC Working Group on Thrombosis. Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. Thromb Haemost. 2012;108(6):1009-22. doi:10.1160/TH12-08-0578.
177. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999;341(11):793-800. doi:10.1056/NEJM199909093411103.
178. Turpie AG. Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. Am J Cardiol. 2000;86(12B):48M-52M. doi:10.1016/s0002-9149(00)01481-8.
179. Ageno W, Turpie AG. Clinical trials of deep vein thrombosis prophylaxis in medical patients. Clin Cornerstone. 2005;7(4):16-22. doi:10.1016/s1098-3597(05)80099-7.
180. Konstantinides SV, Torbicki A, Agnelli G, et al.; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;35(43):3033-69, 3069a-3069k. doi:10.1093/eurheartj/ehu283. Erratum in: Eur Heart J. 2015;36(39):2666. Erratum in: Eur Heart J. 2015;36(39):2642.
181. Agnelli G, Buller HR, Cohen A, et al.; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699-708. doi:10.1056/NEJMoa1207541.
182. Agnelli G, Buller HR, Cohen A, et al.; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808. doi:10.1056/NEJMoa1302507.
183. EINSTEIN—PE Investigators, Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-97. doi:10.1056/NEJMoa1113572.
184. Homma S, Thompson JL, Pullicino PM, et al.; WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med. 2012;366(20):1859-69. doi:10.1056/NEJMoa1202299.
185. Pelliccia A, Fagard R, Bj0rnstad HH, et al.; Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology; Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J. 2005;26(14):1422-45. doi:10.1093/eurheartj/ehi325.
186. Basso C, Carturan E, Corrado D, Thiene G. Myocarditis and dilated cardiomyopathy in athletes: diagnosis, management, and recommendations for sport activity. Cardiol Clin. 2007;25(3):423-9, vi. doi:10.1016/j.ccl.2007.08.008.
187. Schultheiss HP, Piper C, Sowade O, et al. Betaferon in chronic viral cardiomyopathy (BICC) trial: Effects of interferon-в treatment in patients with chronic viral cardiomyopathy. Clin Res Cardiol. 2016;105(9):763-73. doi:10.1007/s00392-016-0986-9.
188. Kuhl U, Lassner D, von Schlippenbach J, et al. Interferon-Beta improves survival in enterovirus-associated cardiomyopathy. J Am Coll Cardiol. 2012;60(14):1295-6. doi:10.1016/j.jacc.2012.06.026.
189. Orange JS, Hossny EM, Weiler CR, et al.; Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117(4 Suppl):S525-53. doi:10.1016/j.jaci.2006.01.015. Erratum in: J Allergy Clin Immunol. 2006;117(6):1483. Dosage error in article text.
190. Gullestad L, Aass H, Fjeld JG, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation. 2001;103(2):220-5. doi:10.1161/01.cir.103.2.220.
191. Drucker NA, Colan SD, Lewis AB, et al. Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation. 1994;89(1):252-7. doi:10.1161/01.cir.89.1.252.
192. McNamara DM, Holubkov R, Starling RC, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 2001;103(18):2254-9. doi:10.1161/01.cir.103.18.2254.
193. Herda LR, Trimpert C, Nauke U, et al. Effects of immunoadsorption and subsequent immunoglobulin G substitution on cardiopulmonary exercise capacity in patients with dilated cardiomyopathy. Am Heart J. 2010;159(5):809-16. doi:10.1016/j.ahj.2010.01.012.
194. Bulut D, Scheeler M, Wichmann T, et al. Effect of protein A immunoadsorption on T cell activation in patients with inflammatory dilated cardiomyopathy. Clin Res Cardiol. 2010;99(10):633-8. doi:10.1007/s00392-010-0162-6.
195. Felix SB, Staudt A, Dorffel WV, et al. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. J Am Coll Cardiol. 2000;35(6):1590-8. doi:10.1016/s0735-1097(00)00568-4.
196. Mobini R, Staudt A, Felix SB, et al. Hemodynamic improvement and removal of autoantibodies against beta1-adrenergic receptor by immunoadsorption therapy in dilated cardiomyopathy. J Autoimmun. 2003;20(4):345-50. doi:10.1016/s0896-8411(03)00042-8.
197. Legrand F, Klion AD. Biologic therapies targeting eosinophils: current status and future prospects. J Allergy Clin Immunol Pract. 2015;3(2):167-74. doi:10.1016/j.jaip.2015.01.013.
198. Maisch B. Cardio-Immunology of Myocarditis: Focus on Immune Mechanisms and Treatment Options. Front Cardiovasc Med. 2019;6:48. doi:10.3389/fcvm.2019.00048.
199. Cooper LT Jr, Hare JM, Tazelaar HD, et al.; Giant Cell Myocarditis Treatment Trial Investigators. Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol. 2008;102(11):1535-9. doi:10.1016/j.amjcard.2008.07.041.
200. Brambatti M, Matassini MV, Adler ED, et al. Eosinophilic Myocarditis: Characteristics, Treatment, and Outcomes. J Am Coll Cardiol. 2017;70(19):2363-75. doi:10.1016/j.jacc.2017.09.023.
201. Ammirati E, Stucchi M, Brambatti M, et al. Eosinophilic myocarditis: a paraneoplastic event. Lancet. 2015;385(9986):2546. doi:10.1016/S0140-6736(15)60903-5.
202. Akuthota P, Weller PF. Spectrum of Eosinophilic End-Organ Manifestations. Immunol Allergy Clin North Am. 2015;35(3):403-11. doi:10.1016/j.iac.2015.04.002.
203. Ogbogu PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 2009;124(6):1319-25.e3. doi:10.1016/j.jaci.2009.09.022.
204. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33(8):1094-100. doi:10.1002/art.1780330806.
205. Miszalski-Jamka T, Szczeklik W, Sokotowska B, et al. Noncorticosteroid immunosuppression limits myocardial damage and contractile dysfunction in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). J Am Coll Cardiol. 2015;65(1):103-5. doi:10.1016/j.jacc.2014.08.055.
206. Yanagisawa T, Inomata T, Watanabe I, et al. Clinical significance of corticosteroid therapy for eosinophilic myocarditis. Int Heart J. 2011;52(2):110-3. doi:10.1536/ihj.52.110.
207. Rothenberg ME, Klion AD, Roufosse FE, et al.; Mepolizumab HES Study Group. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008;358(12):1215-28. doi:10.1056/NEJMoa070812. Erratum in: N Engl J Med. 2008;358(23): 2530.
208. Godsel LM, Leon JS, Wang K, et al. Captopril prevents experimental autoimmune myocarditis. J Immunol. 2003;171(1):346-52. doi:10.4049/jimmunol.171.1.346.
209. Zhang YY, Li JN, Xia HH, et al. Protective effects of losartan in mice with chronic viral myocarditis induced by coxsackievirus B3. Life Sci. 2013;92(24-26):1186-94. doi:10.1016/j.lfs.2013.05.010.
210. Saegusa S, Fei Y, Takahashi T, et al. Oral administration of candesartan improves the survival of mice with viral myocarditis through modification of cardiac adiponectin expression. Cardiovasc Drugs Ther. 2007;21(3):155-60. doi:10.1007/s10557-007-6024-4.
211. Sukumaran V, Watanabe K, Veeraveedu PT, et al. Beneficial effects of olmesartan, an angiotensin II receptor type 1 antagonist, in rats with dilated cardiomyopathy. Exp Biol Med (Maywood). 2010;235(11):1338-46. doi:10.1258/ebm.2010.010016.
212. Piepoli MF, Crisafulli A. Pathophysiology of human heart failure: importance of skeletal muscle myopathy and reflexes. Exp Physiol. 2014;99(4):609-15. doi:10.1113/expphysiol.2013.074310.
213. Ribeiro JP, Chiappa GR, Callegaro CC. The contribution of inspiratory muscles function to exercise limitation in heart failure: pathophysiological mechanisms. Rev Bras Fisioter. 2012;16(4):261-7. English, Portuguese. doi:10.1590/s1413-35552012005000034.
214. Davies EJ, Moxham T, Rees K, et al. Exercise training for systolic heart failure: Cochrane systematic review and meta-analysis. Eur J Heart Fail. 2010;12(7):706-15. doi:10.1093/eurjhf/hfq056.
215. Pandey A, Parashar A, Kumbhani D, et al. Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials. Circ Heart Fail. 2015;8(1):33-40. doi:10.1161/CIRCHEARTFAILURE.114.001615.
216. Corra U, Agostoni PG, Anker SD, et al. Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20(1):3-15. doi:10.1002/ejhf.979. Erratum in: Eur J Heart Fail. 2018;20(10):1501.
217. Bellet RN, Adams L, Morris NR. The 6-minute walk test in outpatient cardiac rehabilitation: validity, reliability and responsiveness — a systematic review. Physiotherapy. 2012;98(4):277-86. doi:10.1016/j.physio.2011.11.003.
218. Арутюнов Г. П. Вопросы немедикаментозного лечения пациентов, страдающих сердечной недостаточностью. Журнал сердечная недостаточность. 2001;2(1):35-6.
219. Callegaro CC, Martinez D, Ribeiro PA, et al. Augmented peripheral chemoreflex in patients with heart failure and inspiratory muscle weakness. Respir Physiol Neurobiol. 2010;171(1):31-5. doi:10.1016/j.resp.2010.01.009.
220. Shah P, Pellicori P, Macnamara A, et al. Is Swimming Safe in Heart Failure? A Systematic Review. Cardiol Rev. 2017;25(6):321-5. doi:10.1097/CRD.0000000000000154.
221. Zamora E, Lupon J, Urrutia A, et al. Estimated creatinine clearance: a determinant prognostic factor in heart failure. Med Clin (Barc). 2008;131(2):47-51. doi:10.1157/13123488.
222. Colwell L, Quinn L. Glycemic control and heart disease. Nurs Clin North Am. 2001;36(2):321-31, vii-viii.
223. Ewid M, Sherif H, Allihimy AS, et al. AST/ALT ratio predicts the functional severity of chronic heart failure with reduced left ventricular ejection fraction. BMC Res Notes. 2020;13(1):178. doi:10.1186/s13104-020-05031-3.
224. Nishimura M, Nakayama K, Ishikawa Y.. Nihon Rinsho. 1996;54(8):2207-12. Japanese.
225. Avanzas P, Arroyo-Espliguero R, Cosm-Sales J, et al. Multiple complex stenoses, high neutrophil count and C-reactive protein levels in patients with chronic stable angina. Atherosclerosis. 2004;175(1):151-7. doi:10.1016/j.atherosclerosis.2004.03.013.
226. Morici N, Cantoni S, Soriano F, et al. Alterazioni dell'emocromo nella sindrome coronarica acuta: ematologi e cardiologi a confronto. G Ital Cardiol (Rome). 2019;20(12):694-705. Italian. doi:10.1714/3271.32379.
227. Núñez J, Miñana G, Bodí V, et al. Low lymphocyte count and cardiovascular diseases. Curr Med Chem. 2011;18(21):3226-33. doi:10.2174/092986711796391633.
228. Bonaque JC, Pascual-Figal DA, Manzano-Fernandez S, et al. Red blood cell distribution width adds prognostic value for outpatients with chronic heart failure. Rev Esp Cardiol (Engl Ed). 2012;65(7):606-12. English, Spanish. doi:10.1016/j.recesp.2011.12.006.
229. Suh S, Cho YR, Park MK, et al. Relationship between serum bilirubin levels and cardiovascular disease. PLoS One. 2018;13(2):e0193041. doi:10.1371/journal.pone.0193041.